Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
The tranSMART Foundation is hosting the Cross Neurodegenerative Diseases Datathon June 30 – July 2. Scientists will use the tranSMART Platform to perform analyses across multiple public datasets in the neurodegenerative disease field, including PPMI, BioFIND, LRRK2, ADNI, and GEO PD.
Dr. Mollenhauer: “[Cerebrospinal fluid] bears the possibility to reflect the underlying biology of the disease process.” Find out what makes the PPMI biospecimens, like cerebrospinal fluid, so important to finding progression markers for PD.
The Study Cohorts page has been updated to give researchers a view of the visit data available for each cohort.
PPMI is excited to announce that several presentations at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS) will feature PPMI data. View the PPMI-related abstracts for this congress happening in San Diego, California on June 14-18.
Nearly 150 PPMI investigators, coordinators, study cores, patient advisory and steering committee members, sponsors, and industry partners from around the world met in New York City May 13-14, 2015 to share PPMI updates and to discuss the future of the initiative. View the meeting’s presentations.